Adjuvant osimertinib delivers sustained long term survival benefit in EGFR mutated NSCLC
Published on 28 September 2026
Dr Roy Herbst speaks to ecancer about updated long-term results from the phase III ADAURA trial.
The results further demonstrate the survival benefit of three years of adjuvant osimertinib in patients with resected EGFR-mutated stage IB-IIIA NSCLC.
In the overall population, the 8-year overall survival rate was 79% with osimertinib versus 64% with placebo, with a 48% reduction in the risk of death.
In patients with stage II-IIIA disease, the 8-year survival rate was 74% versus 58%.
Dr Herbst explores the durability of the survival benefit following completion of adjuvant treatment and outcomes across predefined patient subgroups.
This information is intended for health care professionals only. The information is not intended for US health care professionals.